Precision Antibody Awarded SBIR Contract to Develop High-Affinity, Anti-Peptide Antibodies for SISCAPA Assays

COLUMBIA, Md., November 4, 2014—Precision Antibody, a market leader in contract antibody services, in partnership with SISCAPA Assay Technologies (SAT), has successfully completed a Phase I SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/quantification assays.

Developing these high-affinity reagents and tools for protein biomarker measurement is essential, since there are more than 2,000 potential proteins of interest in cancer research and only 109 protein biomarkers currently cleared by the FDA for diagnostic tests.

“We are excited to partner with SAT," said Precision Antibody President Jun Hayashi. "We believe that SISCAPA is a technology that will change the paradigm of diagnostics and research in cancer as well as a host of other human diseases.”

Under SBIR contract HHSN261201300074C, Precision Antibody successfully developed high affinity mouse monoclonal antibodies to be used as reagents for the SISCAPA technology. This contract relied on Precision Antibody’s three new proprietary technologies: Affinity BoostTM and SMART FusionTM and SeleKDtTM technology. Using these technologies, Precision Antibody developed murine monoclonal antibodies with high affinity and low off-rates, which are not normally achieved in mouse monoclonal antibody development, making them specifically suited for immunoprecipitation and Mass Spectrometry analysis, like SISCAPA.

SAT screened the antibody candidates developed by Precision Antibody and selected the best antibodies for use in SISCAPA applications. SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) is an established technology for targeted protein quantitation that combines antibody-based peptide enrichment with quantitative mass spectrometry. Such technology requires high quality and highly specific antibodies and facilitates multiplexed measurement of proteins from biological samples with unprecedented precision and throughput.

“Precision Antibody continues to push the boundaries of monoclonal antibody development," said Leigh Anderson, chief scientific officer of SAT. "We are excited to work with Dr. Jun Hayashi and his team as they develop the next generation of high-affinity, renewable cancer antibody reagents."

About Precision Antibody

Precision Antibody™ provides customized, high-affinity monoclonal and polyclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions. Precision Antibody develops antibodies for the use in research and discovery, for the development of preclinical therapeutic and diagnostic targets, and for QC and PK studies. The company’s products and services are based on a proprietary antibody discovery and development platform technology that enables rapid development of target-specific, high-affinity antibodies. Precision Antibody provides one-stop service from antigen development, antibody development, antibody characterization (isotype and affinity determination), antibody purification/production (from pilot to large scale), assay development, humanization, stable cell line development and hybridoma cell banking. Precision Antibody is a wholly-owned service division of A&G Pharmaceutical, Inc. and is based in Columbia, MD.

About SISCAPA Assay Technologies, Inc.

SISCAPA Assay Technologies Inc. (SAT) delivers tools for development of high-sensitivity, high-throughput specific assays for proteins, including clinical biomarkers, using SISCAPA® (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology. SISCAPA is a registered trademark of SISCAPA Assay Technologies Inc. in the United States and/or other countries. Additional information about SISCAPA technology, reagents and licensing is available at